论文部分内容阅读
目的:观察积雪苷联合激素及小剂量环磷酰胺治疗系统性硬化症的疗效及安全性。方法:对45例系统性硬化症患者予以积雪苷联合激素及小剂量环磷酰胺治疗。结果患者自我评价的总有效率为82.22%(37/45),其中水肿期、水肿-硬化期和硬化期3组间差异无统计学意义(P>0.05),肢端型的有效率明显高于弥漫型(P<0.01)。医生评价水肿期、水肿-硬化期和硬化期的皮肤紧硬的总得分在治疗后均有明显下降(P<0.01),肢端型也有明显下降(P<0.01),而弥漫型无明显下降(P>0.05)。不良反应发生率为4.44%。结论:积雪苷联合激素及环磷酰胺对治疗肢端型系统性硬化症水肿期和硬化期有良好的近期疗效,且不良反应少。
OBJECTIVE: To observe the efficacy and safety of combination of glucocorticoid and low dose cyclophosphamide in the treatment of systemic sclerosis. Methods: Forty-five patients with systemic sclerosis were treated with combination of glucocorticoid and low-dose cyclophosphamide. Results The total effective rate of self-evaluation was 82.22% (37/45). There was no significant difference between the three groups in edema-sclerosis and sclerosis (P> 0.05), and the effective rate of acromegaly was significantly higher In diffuse type (P <0.01). The physician evaluated the edema-edema-sclerodermal skin sclerosis and sclerosis total scores were significantly decreased after treatment (P <0.01), acromegaly also decreased significantly (P <0.01), while diffuse no significant decline (P> 0.05). The incidence of adverse reactions was 4.44%. CONCLUSION: The combination of glucocorticoid and cyclophosphamide has good short-term curative effect in treating edema and sclerosis of acral systemic sclerosis with less adverse reactions.